

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 14 October 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.

Since the announcement as of 7 October 2019, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	5,221,950		1,820,886,972
7 October 2019	130,000	352.07	45,769,470
8 October 2019	130,000	353.25	45,922,865
9 October 2019	125,000	349.48	43,684,758
10 October 2019	130,000	347.46	45,169,745
11 October 2019	130,000	347.04	45,114,579
Accumulated under the programme	5,866,950		2,046,548,389

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 36,426,994 B shares of DKK 0.20, corresponding to 1.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 11 October, Novo Nordisk has since 1 February 2019 repurchased a total of 29,267,962 B shares at an average share price of DKK 330.79 per B share equal to a transaction value of DKK 9,681,501,843.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 240 9429	kiau@novonordisk.com

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Valdemar Borum Svarrer	+45 3079 0301	jvls@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
Kristoffer Due Berg (US)	+1 609 235 2989	krdb@novonordisk.com